DUALITYBIO-B(09606): Notification of the exercise of the cost and profit/loss sharing option for DB-1311/BNT324

DUALITYBIO-B (09606) announces that on May 12, 2026, the company has issued a written notice to BioNTech SE ("BioNTech"), whose shares are listed on the Nasdaq stock market (Nasdaq code: BNTX), to exercise the exclusive cost and profit/loss sharing option (the "DB-1311/BNT324 cost and profit/loss sharing option") granted to the company under the licensing and cooperation agreement for DB-1311 signed on March 31, 2023. According to the agreement, BioNTech grants the company the right to exercise the exclusive cost and profit/loss sharing option for DB-1311/BNT324 in accordance with the terms of the agreement. The company has the right to exercise this option within a specific period after the successful completion of the first 2 phase clinical trials of the first DB-1311/BNT324 product. After exercising the DB-1311/BNT324 cost and profit/loss sharing option as per the agreement, the company is required to pay BioNTech its share of the past development costs in the United States, and the DB-1311/BNT324 cost and profit/loss sharing option will take effect after the company pays these costs. This enables the company to share the development costs and commercial profits and losses of the first DB-1311/BNT324 product in the US as per the terms of the agreement. The Board believes that DB-1311/BNT324 has shown promising clinical data in multiple oncology indications, and the product has significant commercial potential in the US. Exercising the DB-1311/BNT324 cost and profit/loss sharing option allows the company to harness the potential of DB-1311 in the US, and the exercise of this option is in the best interest of the company and its shareholders overall.